

SEQUENCE LISTING

<110> Haruo Sugiyama

<120> CANCER ANTIGEN PEPTIDE FORMULATIONS

<130> 663970

<140> PCT/JP2003/011675

<141> 2003-09-12

<150> JP 2002-266876

<151> 2002-09-12

<160> 3

<210> 1

<211> 449

<212> PRT

<213> Homo sapiens

<400> 1

Met Gly Ser Asp Val Arg Asp Leu Asn Ala Leu Leu Pro Ala Val Pro
1 5 10 15

Ser Leu Gly Gly Gly Gly Gly Cys Ala Leu Pro Val Ser Gly Ala Ala
20 25 30

Gln Trp Ala Pro Val Leu Asp Phe Ala Pro Pro Gly Ala Ser Ala Tyr
35 40 45

Gly Ser Leu Gly Gly Pro Ala Pro Pro Pro Ala Pro Pro Pro Pro
50 55 60

Pro Pro Pro Pro His Ser Phe Ile Lys Gln Glu Pro Ser Trp Gly Gly
65 70 75 80

Ala Glu Pro His Glu Glu Gln Cys Leu Ser Ala Phe Thr Val His Phe
85 90 95

Ser Gly Gln Phe Thr Gly Thr Ala Gly Ala Cys Arg Tyr Gly Pro Phe
100 105 110

Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln Ala Arg Met Phe
115 120 125

Pro Asn Ala Pro Tyr Leu Pro Ser Cys Leu Glu Ser Gln Pro Ala Ile

130		135		140
Arg Asn Gln Gly Tyr Ser Thr Val Thr Phe Asp Gly Thr Pro Ser Tyr				
145		150		155 160
Gly His Thr Pro Ser His His Ala Ala Gln Phe Pro Asn His Ser Phe				
	165		170	175
Lys His Glu Asp Pro Met Gly Gln Gln Gly Ser Leu Gly Glu Gln Gln				
	180		185	190
Tyr Ser Val Pro Pro Pro Val Tyr Gly Cys His Thr Pro Thr Asp Ser				
	195		200	205
Cys Thr Gly Ser Gln Ala Leu Leu Leu Arg Thr Pro Tyr Ser Ser Asp				
	210		215	220
Asn Leu Tyr Gln Met Thr Ser Gln Leu Glu Cys Met Thr Trp Asn Gln				
	225	230		235 240
Met Asn Leu Gly Ala Thr Leu Lys Gly Val Ala Ala Gly Ser Ser Ser				
	245		250	255
Ser Val Lys Trp Thr Glu Gly Gln Ser Asn His Ser Thr Gly Tyr Glu				
	260		265	270
Ser Asp Asn His Thr Thr Pro Ile Leu Cys Gly Ala Gln Tyr Arg Ile				
	275		280	285
His Thr His Gly Val Phe Arg Gly Ile Gln Asp Val Arg Arg Val Pro				
	290		295	300
Gly Val Ala Pro Thr Leu Val Arg Ser Ala Ser Glu Thr Ser Glu Lys				
	305	310		315 320
Arg Pro Phe Met Cys Ala Tyr Pro Gly Cys Asn Lys Arg Tyr Phe Lys				
	325		330	335
Leu Ser His Leu Gln Met His Ser Arg Lys His Thr Gly Glu Lys Pro				
	340		345	350
Tyr Gln Cys Asp Phe Lys Asp Cys Glu Arg Arg Phe Ser Arg Ser Asp				
	355		360	365
Gln Leu Lys Arg His Gln Arg Arg His Thr Gly Val Lys Pro Phe Gln				
	370		375	380
Cys Lys Thr Cys Gln Arg Lys Phe Ser Arg Ser Asp His Leu Lys Thr				

385		390		395		400
His Thr Arg Thr	His Thr Gly Lys Thr	Ser Glu Lys Pro Phe	Ser Cys			
	405	410	415			
Arg Trp Pro Ser	Cys Gln Lys Lys Phe	Ala Arg Ser Asp	Glu Leu Val			
	420	425	430			
Arg His His Asn Met	His Gln Arg Asn Met	Thr Lys Leu	Gln Leu Ala			
	435	440	445			

Leu

<210> 2
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 2
 Cys Met Thr Trp Asn Gln Met Asn Leu
 .1 5

<210> 3
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic Peptide

<400> 3
 Cys Tyr Thr Trp Asn Gln Met Asn Leu
 1 5